Global Treatment for Communicable Diseases

Treatment for Communicable Diseases Comprehensive Study by Type (Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others), Vaccines), Application (Hospital, Clinic, Other), Diseases (Contact Communicable Diseases, Sexually Transmitted Diseases, Oral Contamination Diseases, Helminthic Diseases, Air Borne Diseases), Infectious Agent (Bacteria, Viruses, Fungi/Parasites) Players and Region - Global Market Outlook to 2030

Treatment for Communicable Diseases Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Treatment for Communicable Diseases
The treatment for communicable diseases market is expected to grow during the forecast period owing to the rising prevalence of sexually transmitted diseases, growing awareness regarding communicable diseases. Also growing public and private partnerships for research of new therapies is boosting in the market. The treatment approach for a communicable disease depends on the type of pathogen, severity of symptoms, individual health factors, and potential allergies or drug interactions. Always consult a healthcare professional for diagnosis and proper treatment guidance.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The key manufacturers are targeting the innovations of the products with better quality, better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking upon mergers and acquisitions in order to maintain their presence in the market. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Treatment for Communicable Diseases market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis AG (Switzerland), Gilead Sciences, Inc (United States), Pfizer Inc. (United States), GlaxoSmithKline plc (United Kingdom), Janssen Pharmaceutical, Inc.(Belgium), Merck & Co., Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (United Kingdom), BioCryst Pharmaceuticals, Inc. (United States) and Sanofi (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Mylan N.V. (United States), C.H. Boehringer Sohn AG & Ko (Germany), Cipla (India) and Lupin (India).

Segmentation Overview
AMA Research has segmented the market of Global Treatment for Communicable Diseases market by Type (Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others) and Vaccines), Application (Hospital, Clinic and Other) and Region.



On the basis of geography, the market of Treatment for Communicable Diseases has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diseases , the sub-segment i.e. Contact Communicable Diseases will boost the Treatment for Communicable Diseases market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Infectious Agent, the sub-segment i.e. Bacteria will boost the Treatment for Communicable Diseases market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Introduction of New Treatments and Products

Market Growth Drivers:
Rising Incidence of Infectious Diseases and Growing Government Initiatives to Keep the nation safe from diseases

Challenges:
Side Effects of the Drugs

Restraints:
High Cost of Treatment and Lack of reimbursement in selected countries

Opportunities:
Increasing Research and Development Activities for New Product Development and Rising Funding for the Research and Development

Market Leaders and their expansionary development strategies
In October 2023, WHO collaborates with UNICEF and other partners to launch a global campaign to vaccinate 50 million children against hepatitis B by 2025.
In September 2023, WHO pre-qualifies Novartis' Kymriah (tisagenlecleucel) therapy for the treatment of acute lymphoblastic leukemia (ALL), making it accessible to low- and middle-income countries.


Key Target Audience
Treatment Provider, Pharmaceuticals Industries, Research and Development Organization and Potential Investors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others)
  • Vaccines
By Application
  • Hospital
  • Clinic
  • Other
By Diseases
  • Contact Communicable Diseases
  • Sexually Transmitted Diseases
  • Oral Contamination Diseases
  • Helminthic Diseases
  • Air Borne Diseases

By Infectious Agent
  • Bacteria
  • Viruses
  • Fungi/Parasites

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Infectious Diseases
      • 3.2.2. Growing Government Initiatives to Keep the nation safe from diseases
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of the Drugs
    • 3.4. Market Trends
      • 3.4.1. Introduction of New Treatments and Products
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Treatment for Communicable Diseases, by Type, Application, Diseases , Infectious Agent and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Treatment for Communicable Diseases (Value)
      • 5.2.1. Global Treatment for Communicable Diseases by: Type (Value)
        • 5.2.1.1. Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others)
        • 5.2.1.2. Vaccines
      • 5.2.2. Global Treatment for Communicable Diseases by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Other
      • 5.2.3. Global Treatment for Communicable Diseases by: Infectious Agent (Value)
        • 5.2.3.1. Bacteria
        • 5.2.3.2. Viruses
        • 5.2.3.3. Fungi/Parasites
      • 5.2.4. Global Treatment for Communicable Diseases Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Treatment for Communicable Diseases (Price)
      • 5.3.1. Global Treatment for Communicable Diseases by: Type (Price)
  • 6. Treatment for Communicable Diseases: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Gilead Sciences, Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Janssen Pharmaceutical, Inc.(Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BioCryst Pharmaceuticals, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Treatment for Communicable Diseases Sale, by Type, Application, Diseases , Infectious Agent and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Treatment for Communicable Diseases (Value)
      • 7.2.1. Global Treatment for Communicable Diseases by: Type (Value)
        • 7.2.1.1. Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others)
        • 7.2.1.2. Vaccines
      • 7.2.2. Global Treatment for Communicable Diseases by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Other
      • 7.2.3. Global Treatment for Communicable Diseases by: Infectious Agent (Value)
        • 7.2.3.1. Bacteria
        • 7.2.3.2. Viruses
        • 7.2.3.3. Fungi/Parasites
      • 7.2.4. Global Treatment for Communicable Diseases Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Treatment for Communicable Diseases (Price)
      • 7.3.1. Global Treatment for Communicable Diseases by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Treatment for Communicable Diseases: by Type(USD Million)
  • Table 2. Treatment for Communicable Diseases Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others) , by Region USD Million (2018-2023)
  • Table 3. Treatment for Communicable Diseases Vaccines , by Region USD Million (2018-2023)
  • Table 4. Treatment for Communicable Diseases: by Application(USD Million)
  • Table 5. Treatment for Communicable Diseases Hospital , by Region USD Million (2018-2023)
  • Table 6. Treatment for Communicable Diseases Clinic , by Region USD Million (2018-2023)
  • Table 7. Treatment for Communicable Diseases Other , by Region USD Million (2018-2023)
  • Table 8. Treatment for Communicable Diseases: by Infectious Agent(USD Million)
  • Table 9. Treatment for Communicable Diseases Bacteria , by Region USD Million (2018-2023)
  • Table 10. Treatment for Communicable Diseases Viruses , by Region USD Million (2018-2023)
  • Table 11. Treatment for Communicable Diseases Fungi/Parasites , by Region USD Million (2018-2023)
  • Table 12. South America Treatment for Communicable Diseases, by Country USD Million (2018-2023)
  • Table 13. South America Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 14. South America Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 15. South America Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 16. South America Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 17. Brazil Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 18. Brazil Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 19. Brazil Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 20. Brazil Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 21. Argentina Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 22. Argentina Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 23. Argentina Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 24. Argentina Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 25. Rest of South America Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 26. Rest of South America Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 27. Rest of South America Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 28. Rest of South America Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 29. Asia Pacific Treatment for Communicable Diseases, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 32. Asia Pacific Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 33. Asia Pacific Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 34. China Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 35. China Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 36. China Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 37. China Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 38. Japan Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 39. Japan Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 40. Japan Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 41. Japan Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 42. India Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 43. India Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 44. India Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 45. India Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 46. South Korea Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 47. South Korea Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 48. South Korea Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 49. South Korea Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 50. Taiwan Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 51. Taiwan Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 52. Taiwan Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 53. Taiwan Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 54. Australia Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 55. Australia Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 56. Australia Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 57. Australia Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 58. Rest of Asia-Pacific Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 59. Rest of Asia-Pacific Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 62. Europe Treatment for Communicable Diseases, by Country USD Million (2018-2023)
  • Table 63. Europe Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 64. Europe Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 65. Europe Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 66. Europe Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 67. Germany Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 68. Germany Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 69. Germany Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 70. Germany Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 71. France Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 72. France Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 73. France Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 74. France Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 75. Italy Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 76. Italy Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 77. Italy Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 78. Italy Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 79. United Kingdom Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 80. United Kingdom Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 81. United Kingdom Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 82. United Kingdom Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 83. Netherlands Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 84. Netherlands Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 85. Netherlands Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 86. Netherlands Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 87. Rest of Europe Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 88. Rest of Europe Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 89. Rest of Europe Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 90. Rest of Europe Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 91. MEA Treatment for Communicable Diseases, by Country USD Million (2018-2023)
  • Table 92. MEA Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 93. MEA Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 94. MEA Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 95. MEA Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 96. Middle East Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 97. Middle East Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 98. Middle East Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 99. Middle East Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 100. Africa Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 101. Africa Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 102. Africa Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 103. Africa Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 104. North America Treatment for Communicable Diseases, by Country USD Million (2018-2023)
  • Table 105. North America Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 106. North America Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 107. North America Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 108. North America Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 109. United States Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 110. United States Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 111. United States Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 112. United States Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 113. Canada Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 114. Canada Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 115. Canada Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 116. Canada Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 117. Mexico Treatment for Communicable Diseases, by Type USD Million (2018-2023)
  • Table 118. Mexico Treatment for Communicable Diseases, by Application USD Million (2018-2023)
  • Table 119. Mexico Treatment for Communicable Diseases, by Diseases USD Million (2018-2023)
  • Table 120. Mexico Treatment for Communicable Diseases, by Infectious Agent USD Million (2018-2023)
  • Table 121. Treatment for Communicable Diseases: by Type(USD/Units)
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Treatment for Communicable Diseases: by Type(USD Million)
  • Table 133. Treatment for Communicable Diseases Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others) , by Region USD Million (2025-2030)
  • Table 134. Treatment for Communicable Diseases Vaccines , by Region USD Million (2025-2030)
  • Table 135. Treatment for Communicable Diseases: by Application(USD Million)
  • Table 136. Treatment for Communicable Diseases Hospital , by Region USD Million (2025-2030)
  • Table 137. Treatment for Communicable Diseases Clinic , by Region USD Million (2025-2030)
  • Table 138. Treatment for Communicable Diseases Other , by Region USD Million (2025-2030)
  • Table 139. Treatment for Communicable Diseases: by Infectious Agent(USD Million)
  • Table 140. Treatment for Communicable Diseases Bacteria , by Region USD Million (2025-2030)
  • Table 141. Treatment for Communicable Diseases Viruses , by Region USD Million (2025-2030)
  • Table 142. Treatment for Communicable Diseases Fungi/Parasites , by Region USD Million (2025-2030)
  • Table 143. South America Treatment for Communicable Diseases, by Country USD Million (2025-2030)
  • Table 144. South America Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 145. South America Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 146. South America Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 147. South America Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 148. Brazil Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 149. Brazil Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 150. Brazil Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 151. Brazil Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 152. Argentina Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 153. Argentina Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 154. Argentina Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 155. Argentina Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 156. Rest of South America Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 157. Rest of South America Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 158. Rest of South America Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 159. Rest of South America Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 160. Asia Pacific Treatment for Communicable Diseases, by Country USD Million (2025-2030)
  • Table 161. Asia Pacific Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 162. Asia Pacific Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 163. Asia Pacific Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 164. Asia Pacific Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 165. China Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 166. China Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 167. China Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 168. China Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 169. Japan Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 170. Japan Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 171. Japan Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 172. Japan Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 173. India Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 174. India Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 175. India Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 176. India Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 177. South Korea Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 178. South Korea Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 179. South Korea Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 180. South Korea Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 181. Taiwan Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 182. Taiwan Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 183. Taiwan Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 184. Taiwan Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 185. Australia Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 186. Australia Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 187. Australia Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 188. Australia Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 189. Rest of Asia-Pacific Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 190. Rest of Asia-Pacific Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 191. Rest of Asia-Pacific Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 193. Europe Treatment for Communicable Diseases, by Country USD Million (2025-2030)
  • Table 194. Europe Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 195. Europe Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 196. Europe Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 197. Europe Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 198. Germany Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 199. Germany Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 200. Germany Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 201. Germany Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 202. France Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 203. France Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 204. France Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 205. France Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 206. Italy Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 207. Italy Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 208. Italy Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 209. Italy Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 210. United Kingdom Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 211. United Kingdom Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 212. United Kingdom Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 213. United Kingdom Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 214. Netherlands Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 215. Netherlands Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 216. Netherlands Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 217. Netherlands Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 218. Rest of Europe Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 219. Rest of Europe Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 220. Rest of Europe Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 221. Rest of Europe Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 222. MEA Treatment for Communicable Diseases, by Country USD Million (2025-2030)
  • Table 223. MEA Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 224. MEA Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 225. MEA Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 226. MEA Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 227. Middle East Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 228. Middle East Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 229. Middle East Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 230. Middle East Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 231. Africa Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 232. Africa Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 233. Africa Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 234. Africa Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 235. North America Treatment for Communicable Diseases, by Country USD Million (2025-2030)
  • Table 236. North America Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 237. North America Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 238. North America Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 239. North America Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 240. United States Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 241. United States Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 242. United States Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 243. United States Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 244. Canada Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 245. Canada Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 246. Canada Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 247. Canada Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 248. Mexico Treatment for Communicable Diseases, by Type USD Million (2025-2030)
  • Table 249. Mexico Treatment for Communicable Diseases, by Application USD Million (2025-2030)
  • Table 250. Mexico Treatment for Communicable Diseases, by Diseases USD Million (2025-2030)
  • Table 251. Mexico Treatment for Communicable Diseases, by Infectious Agent USD Million (2025-2030)
  • Table 252. Treatment for Communicable Diseases: by Type(USD/Units)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Treatment for Communicable Diseases: by Type USD Million (2018-2023)
  • Figure 5. Global Treatment for Communicable Diseases: by Application USD Million (2018-2023)
  • Figure 6. Global Treatment for Communicable Diseases: by Infectious Agent USD Million (2018-2023)
  • Figure 7. South America Treatment for Communicable Diseases Share (%), by Country
  • Figure 8. Asia Pacific Treatment for Communicable Diseases Share (%), by Country
  • Figure 9. Europe Treatment for Communicable Diseases Share (%), by Country
  • Figure 10. MEA Treatment for Communicable Diseases Share (%), by Country
  • Figure 11. North America Treatment for Communicable Diseases Share (%), by Country
  • Figure 12. Global Treatment for Communicable Diseases: by Type USD/Units (2018-2023)
  • Figure 13. Global Treatment for Communicable Diseases share by Players 2023 (%)
  • Figure 14. Global Treatment for Communicable Diseases share by Players (Top 3) 2023(%)
  • Figure 15. Global Treatment for Communicable Diseases share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. Gilead Sciences, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 20. Gilead Sciences, Inc (United States) Revenue: by Geography 2023
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 23. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 25. Janssen Pharmaceutical, Inc.(Belgium) Revenue, Net Income and Gross profit
  • Figure 26. Janssen Pharmaceutical, Inc.(Belgium) Revenue: by Geography 2023
  • Figure 27. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 29. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 31. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 33. BioCryst Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. BioCryst Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 36. Sanofi (France) Revenue: by Geography 2023
  • Figure 37. Global Treatment for Communicable Diseases: by Type USD Million (2025-2030)
  • Figure 38. Global Treatment for Communicable Diseases: by Application USD Million (2025-2030)
  • Figure 39. Global Treatment for Communicable Diseases: by Infectious Agent USD Million (2025-2030)
  • Figure 40. South America Treatment for Communicable Diseases Share (%), by Country
  • Figure 41. Asia Pacific Treatment for Communicable Diseases Share (%), by Country
  • Figure 42. Europe Treatment for Communicable Diseases Share (%), by Country
  • Figure 43. MEA Treatment for Communicable Diseases Share (%), by Country
  • Figure 44. North America Treatment for Communicable Diseases Share (%), by Country
  • Figure 45. Global Treatment for Communicable Diseases: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Gilead Sciences, Inc (United States)
  • Pfizer Inc. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Janssen Pharmaceutical, Inc.(Belgium)
  • Merck & Co., Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AstraZeneca (United Kingdom)
  • BioCryst Pharmaceuticals, Inc. (United States)
  • Sanofi (France)
Additional players considered in the study are as follows:
Mylan N.V. (United States) , C.H. Boehringer Sohn AG & Ko (Germany) , Cipla (India) , Lupin (India)
Select User Access Type

Key Highlights of Report


Jan 2024 225 Pages 80 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Treatment for Communicable Diseases Quantitative research analysis
Global Treatment for Communicable Diseases Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis AG (Switzerland), Gilead Sciences, Inc (United States), Pfizer Inc. (United States), GlaxoSmithKline plc (United Kingdom), Janssen Pharmaceutical, Inc.(Belgium), Merck & Co., Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (United Kingdom), BioCryst Pharmaceuticals, Inc. (United States) and Sanofi (France) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Introduction of New Treatments and Products" is seen as one of major influencing trends for Treatment for Communicable Diseases Market during projected period 2023-2030.
The Treatment for Communicable Diseases market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Treatment for Communicable Diseases Report?

Have a Query? Click Here

Other Related Reports

Injectable Anti-Wrinkle Comprehensive Study by Type (Muscle Relaxants (Botox Injections, Others), Synthetic Wrinkle Fillers (Sculptra, Radiesse, Silicone), Autologous Wrinkle Fillers, Muscle Relaxant...
$ 3750
Unna Boot Comprehensive Study by Application (Venous Leg Ulcers, Lymphedema, Eczema), Raw Material (Zinc Oxide, Zinc, Calamine), Distribution Channel (Offline Retail, Online Retail) Players and Regi...
$ 3500
RNA Based Therapeutics Comprehensive Study by Application (Cardiovascular, Kidney Diseases, Oncology, Infectious Diseases, Metabolic Disorders, Others), Technology (Inhibition, Microarrays, Labeling,...
$ 3650
Cancer Biological Therapy Comprehensive Study by Type (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Blood Cell Growth Factors), Application (Hospitals, Diagnostic Laboratories, Research &...
$ 3650
Ascites Comprehensive Study by Type (Exudate Ascites, Transudative Ascites), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostics Centers, Others), Diagnosis (Angiography, Ultras...
$ 3650
Acute Intermittent Porphyria Comprehensive Study by Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions, Others), Diagnosis (Blood Test, Urine Test, DNA Test, Serum Te...
$ 3450